Table 3.
The effects of PEG-rhG-CSF and rhG-CSF on ASCT related adverse reactions prior to short-term hematopoietic reconstitution and mortality within 100 days post-transplant.
| PEG-rhG-CSF | rhG-CSF | p value | |
|---|---|---|---|
| Hematologic toxicity | |||
| Neutropenia, n (%) | > 0.999 | ||
| Grade I–II | 0 | 0 | |
| Grade III–IV | 33 (100%) | 37 (100%) | |
| Anemia, n (%) | 0.832 | ||
| Grade I–II | 17 (51.5%) | 20 (54.1%) | |
| Grade III–IV | 0 | 0 | |
| Thrombocytopenia, n (%) | > 0.999 | ||
| Grade I–II | 0 | 0 | |
| Grade III–IV | 100% | 100% | |
| Non-hematological toxicity | |||
| Fever, n (%) | 21 (63.6%) | 18 (48.6%) | 0.157 |
| Gastrointestinal toxicity | |||
| Nausea and vomiting, n (%) | 0.379 | ||
| Grade I–II | 27 (81.8%) | 27 (73%) | |
| Grade III–IV | 0 | 0 | |
| Diarrhea, n (%) | 0.006 | ||
| Grade I–II | 10 (30.3%) | 23 (62.2%) | |
| Grade III–IV | 20 (60.6%) | 11 (29.7%) | |
| Hepatotoxicity | |||
| Elevated transaminase, n (%) | 0.726 | ||
| Grade I–II | 5 (15.2%) | 4 (10.8%) | |
| Grade III–IV | 0 | 0 | |
| Elevated bilirubin, n (%) | 0.790 | ||
| Grade I–II | 8 (24.2%) | 10 (27%) | |
| Grade III–IV | 0 | 0 | |
| Renal toxicity | |||
| Elevated blood creatinine, n (%) | 0.677 | ||
| Grade I–II | 2 (6.1%) | 4 (10.8%) | |
| Grade III–IV | 0 | 0 | |
| Bacterial pathogens, n (%) | 0.093 | ||
| Gram-positive bacteria, n (%) | 0 | 0 | |
| Gram-negative bacteria, n (%) | 5 (15.2%) | 1 (2.7%) | |
| Median days of diarrhea, n (range) | 9 (0–22) | 6 (0–15) | 0.004 |
| Median days of nausea and vomiting, n (range) | 5 (0–27) | 4 (0–12) | 0.141 |
| Days of intravenous nutrition, n (range) | 7 (0–22) | 6 (0–17) | 0.574 |
| Death within 100 days post-transplant, n (%) | 0 | 0 | |
PEG-rhG-CSF, Polyethylene glycolized recombinant human granulocyte-stimulating factor; rhG-CSF, Recombinant human granulocyte-stimulating factor.
Significant values are in italics